AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2022
Jun 15, 2022
33390_dirs_2022-06-14_7c2647aa-0eb7-4f09-ab83-a3acecd3b4d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2022-06-13
Reporting Person: Mitchell Stephen Ray (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-13 | Common Stock | S | 2700 | $9.4789 | Disposed | 6515 | Direct |
Footnotes
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.431 to $9.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.